Medicamen Biotech share price, P/E, ROE & financials

Medicamen Biotech (MEDICAMEQ) had a P/E of 37.2× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 38% below their 52-week high. Its ROCE of 5.5% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 12% a year over 3 years while net profit fell 13%. Its dividend yield is 0.4%, and debt is 0.17× equity. It is a small-cap company with a market cap of ₹388 Cr, ranked 84th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 32% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹260.00
Day high: ₹275.70
Day low: ₹254.00
Prev. close: ₹262.60
Volume: 16.7K

Health check

2 fair · 4 to check

ReturnsBehind
−31.7% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 37.2 vs industry 28.7.
GrowthSteady
Sales +12.0%, profit −13.4% a year over 3 years.
ProfitabilityWeak
ROCE 5.5% vs peer median 17.9%.
Balance sheetFair
Debt 0.17× equity, interest covered 4.4×, Piotroski 4 of 9.
Red flags2 to check
Return on equity is low at 4.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹388 Cr, #84 of 154 in its industry by size.

Defensive

Beta 0.79 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹206 Cr · profit ₹10 Cr

Market cap: ₹388 Cr; Small cap
P/E: 37.2; Industry 28.7
Price to book: 1.18; Peers 4.99
Dividend yield: 0.36%
ROE: 4.0%; Peers 14.7%
ROCE: 5.5%; Peers 17.9%
Debt to equity: 0.17; Debt ₹48 Cr
EPS (TTM): ₹7.41; Face value ₹10
OPM (TTM): 9.5%; Net margin 4.7%
Sales growth: +11.3%; Latest quarter vs a year ago
Profit growth: −1.6%; Latest quarter vs a year ago
Price to sales: 1.88; EV/EBITDA 19.5

Strengths

Promoter stake up from 40.5% to 42.6%.

Risks to check

Return on equity is low at 4.0%.
38% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Medicamen Biotech

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, and sells pharmaceutical formulations in India and internationally. The company provides tablets, capsules, dry syrups, oral liquids, ointments, and other pharmaceutical dosage forms. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins and supplements, antibiotics, pain…

Headquarters: New Delhi
Employees: 405
Sector: Healthcare
ISIN: INE646B01010
Website: medicamen.com

Price range

52 weeks

₹212.40₹447.65

Today

₹254.00₹275.70

Avg volume (3M): 48.7K
1-year return: minus 31.7%
From 52-week high: minus 38.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
MEDICAMEQMedicamen Biotech	275.70	plus 4.99%	388	37.2	1.18	5.5%	4.0%	9.5%	12.0%	−13.4%	0.36%	minus 31.7%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
43	47.2	46.9	60.6	47.9
38.4	42	42.5	55.2	43.6
4.6	5.2	4.4	5.4	4.3
10.7%	10.9%	9.3%	9.0%	9.0%
0.5	0.4	0.5	1.7	0.9
1.2	1	1	0.4	0.8
1.8	1.9	1.8	1.7	1.8
2.1	2.7	2.1	5.1	2.6
24.9%	21.2%	22.6%	12.1%	28.2%
2.2	2.7	1.6	3.9	2.1
1.18	1.56	1.21	3.28	1.36

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +12.0%
Profit CAGR 3Y: −13.4%
EPS CAGR 3Y: −15.4%
ROE: 4.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
141	179	163	198
–	+27.3%	minus 9.3%	+21.7%
116	155	143	177
25.3	24.5	19.3	20.8
17.9%	13.7%	11.9%	10.5%
2	1	0.7	2
2.9	4.4	3.2	3.5
6.4	7.1	6.9	7.2
−0.9	−0.9	−0	−0
17	13.1	9.9	12
13.6%	27.4%	33.6%	18.3%
14.8	10.9	7.1	9.6
–	minus 26.4%	minus 35.0%	+35.6%
11.73	8.63	5.59	7.11

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
12.7	12.7	12.7	13.6
181	192	199	259
25.7	31.1	33.8	49.2
59.4	58.3	51.5	49.8
279	295	297	372
91.8	91	86.4	84.1
20.8	14.8	3.8	31.3
166	189	207	257
279	295	297	372

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−6.3	−6.7	−8.2	−33.2
−5.9	−5.6	−1.4	−3
29.1	6.3	−1.5	63.7
17	−6	−11	27.5
−6.6	−6.3	−2.2	−4.8
−12.9	−13	−10.3	−38
−1.3	−1.3	−1.3	−1.4

Shareholding pattern

Source: NSE filings

42.6%

promoters

Promoters42.57%
Public57.43%
As of 23 Oct 2026

Quarter	Promoters	Public	Promoter change
23 Oct 2026	42.57%	57.43%	plus 2.11
30 Sep 2026	40.46%	59.54%	0.00
30 Jun 2026	40.46%	59.54%	0.00
31 Mar 2026	40.46%	59.54%	0.00
31 Dec 2025	40.46%	59.54%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you